Nov 5 (Reuters) - Pfizer (PFE.N), opens new tab is preparing to sweeten its offer again for Metsera (MTSR.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Pfizer (NYSE:PFE) is preparing to release its quarterly earnings on Tuesday, 2025-11-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Pfizer ...

SAN FRANCISCO ― Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...